Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer

doi:10.4251/wjgo.v11.i11.1065

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8133)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

431

WORD

254

HTML

4968

Figures (1-3)

255

Tables (1-4)

210

Sum=6118

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

654

Download

1361

Sum=2015

Nov 15, 2019 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1065-1080
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065

Table 4 Predictive factors for survival in univariate and multivariate analyses

Observation	Univariate			Multivariate
Observation	P	HR	95%CI	P	HR	95%CI
Model 1^a
MLH1/MSH2 negative
Operation vs Operation + Chemotherapy	0.098	1.021	0.342-2.741	0.147	1.563	0.481-4.441
MLH1/MSH2 positive
Operation vs Operation + Chemotherapy	0.081	1.899	0.127-4.114	0.070	1.267	0.212-5.052
Model 2^b
MLH1/MSH2 negative
Operation vs Operation + Chemotherapy	0.001	4.393	2.068-12.316	< 0.001	7.660	2.974-15.883
MLH1/MSH2 positive
Operation vs Operation + Chemotherapy	0.063	2.015	0.648-5.997	0.052	2.817	0.223-6.671

^a395 Patients with stage II CRC;

^b286 Patients with stage III CRC. HR: hazard ratio; CI: confidence interval; MLH1: MutL homolog 1; MSH2: MutS homolog 2.

Citation: Wang SM, Jiang B, Deng Y, Huang SL, Fang MZ, Wang Y. Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer. World J Gastrointest Oncol 2019; 11(11): 1065-1080
URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1065.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1065